• Progentos Therapeutics dosed the first participant in its Phase 1/2a trial of PRO-1562, an oral drug designed to regenerate myelin.
• The Phase 1 study in healthy adults at one Australian site will assess safety, tolerability, pharmacokinetics and central nervous system penetration.
• A six-month Phase 2a trial will test once-monthly dosing in adults with relapsing multiple sclerosis and chronic optic neuropathy for remyelination.
• Both trial phases are randomized, double-blind and placebo-controlled.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forbion Capital Partners Management Services BV published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.